Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential ...

Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.

More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

March is National Kidney Month, a time to shine a light on the thousands of individuals whose lives are deeply affected by ...

The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.

Acute kidney injury (AKI) in patients with lupus nephritis is tied with rapid disease worsening and potential progression to chronic kidney disease and kidney failure.

Kyleigh MacGregor plans her life five years at a time. MacGregor has lupus, an incurable disease in which her immune system attacks her body’s organs and tissue. It’s been a year since MacGregor, 31, ...

A doctor advising ... sleepaway camp? That’s how a 12-year-old diagnosed with lupus found himself laughing on a high-ropes course as fellow campers hoisted him into the air. “It’s really fun,” said ...

Autoimmune disease hair loss can happen with alopecia areata, lupus, thyroid diseases, rheumatoid arthritis, Crohn’s disease, and scalp psoriasis. Each disease has different effects, ...